ZIOPHARM commences early-stage study of gene therapy Ad-RTS-hIL-12 in pediatric brain tumors – Seeking Alpha
|
ZIOPHARM commences early-stage study of gene therapy Ad-RTS-hIL-12 in pediatric brain tumors
Seeking Alpha Ad-RTS-hIL-12 is a novel gene therapy candidate for the controlled expression of interleukin-12 (IL-12), an essential protein for stimulating a T cell immune response to cancer. Veledimex is an oral activator ligand or "gene switch" which is used to … ZIOPHARM Oncology Announces First Patient Dosed in New Phase 1 Study of Ad-RTS-hIL-12 plus Veledimex for the … |
